Repligen Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Repligen stock.
View analyst ratings for Repligen or view top-rated stocks.

6 Wall Street analysts have issued 1-year price targets for Repligen's stock. Their RGEN stock forecasts range from $250.00 to $335.00. On average, they predict Repligen's stock price to reach $301.50 in the next twelve months. This suggests a possible upside of 81.1% from the stock's current price.
View analysts' price targets for Repligen or view top-rated stocks among Wall Street analysts.

Repligen's stock was trading at $264.84 at the beginning of the year. Since then, RGEN shares have decreased by 37.1% and is now trading at $166.52.
View the best growth stocks for 2022 here.

Repligen is scheduled to release its next quarterly earnings announcement on Tuesday, July 26th 2022.
View our earnings forecast for Repligen.

Repligen Co. (NASDAQ:RGEN) released its quarterly earnings results on Wednesday, April, 27th. The biotechnology company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.20. The biotechnology company earned $206.40 million during the quarter, compared to analyst estimates of $185.48 million. Repligen had a net margin of 19.86% and a trailing twelve-month return on equity of 11.13%. The company's quarterly revenue was up 44.5% on a year-over-year basis. During the same period last year, the company posted $0.68 EPS.
View Repligen's earnings history.

Repligen issued an update on its FY22 earnings guidance on Wednesday, April, 27th. The company provided earnings per share guidance of $3.07-3.15 for the period, compared to the consensus EPS estimate of $3.25. The company issued revenue guidance of $770-800 million, compared to the consensus revenue estimate of $820.31 million.

13 employees have rated Repligen CEO Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among Repligen's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Repligen include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Exelixis (EXEL), Halozyme Therapeutics (HALO) and Ionis Pharmaceuticals (IONS).
View all of RGEN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Square (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RGEN stock can currently be purchased for approximately $166.52.

Repligen (NASDAQ:RGEN) has a market capitalization of $9.06 billion and generates $670.53 million in revenue each year. The biotechnology company earns $128.29 million in net income (profit) each year or $2.529990 on an earnings per share basis.

Repligen employs 1,852 workers across the globe.

Repligen was founded in 1981.

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The official website for Repligen is www.repligen.com. The biotechnology company can be reached via phone at (781) 250-0111, via email at investors@repligen.com, or via fax at 781-250-0115.